SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-040628
Filing Date
2024-05-08
Accepted
2024-05-08 07:00:49
Documents
50
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0204680-6k_kamada.htm   iXBRL 6-K 23052
2 KAMADA REPORTS STRONG FIRST QUARTER 2024 FINANCIAL RESULTS WITH YEAR-OVER-YEAR T ea020468001ex99-1_kamada.htm EX-99.1 161602
3 COMPANY'S PRESENTATION MAY 2024 ea020468001ex99-2_kamada.htm EX-99.2 17802
4 KAMADA LTD'S CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 (UNAUDITED) ea020468001ex99-3_kamada.htm   iXBRL EX-99.3 440413
5 GRAPHIC ex99-2_001.jpg GRAPHIC 248418
6 GRAPHIC ex99-2_002.jpg GRAPHIC 1175644
7 GRAPHIC ex99-2_003.jpg GRAPHIC 492608
8 GRAPHIC ex99-2_004.jpg GRAPHIC 422447
9 GRAPHIC ex99-2_005.jpg GRAPHIC 642632
10 GRAPHIC ex99-2_006.jpg GRAPHIC 654329
11 GRAPHIC ex99-2_007.jpg GRAPHIC 542083
12 GRAPHIC ex99-2_008.jpg GRAPHIC 758871
13 GRAPHIC ex99-2_009.jpg GRAPHIC 670040
14 GRAPHIC ex99-2_010.jpg GRAPHIC 109319
15 GRAPHIC ex99-2_011.jpg GRAPHIC 399028
  Complete submission text file 0001213900-24-040628.txt   10930802

Data Files

Seq Description Document Type Size
16 XBRL SCHEMA FILE kmda-20240331.xsd EX-101.SCH 30760
17 XBRL CALCULATION FILE kmda-20240331_cal.xml EX-101.CAL 40897
18 XBRL DEFINITION FILE kmda-20240331_def.xml EX-101.DEF 110570
19 XBRL LABEL FILE kmda-20240331_lab.xml EX-101.LAB 256054
20 XBRL PRESENTATION FILE kmda-20240331_pre.xml EX-101.PRE 116150
53 EXTRACTED XBRL INSTANCE DOCUMENT ea0204680-6k_kamada_htm.xml XML 307728
Mailing Address 2 HOLTZMAN ST., SCIENCE PARK REHOVOT L3 7670402
Business Address 2 HOLTZMAN ST., SCIENCE PARK REHOVOT L3 7670402 97289406472
KAMADA LTD (Filer) CIK: 0001567529 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-35948 | Film No.: 24924180
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)